By vgreene, 21 April, 2020 Bronchiectasis. Evidence as mucolytic for non-CF bronchiectasis insufficient;10 NAC NEB may preserve lung fxn in CF11
By vgreene, 21 April, 2020 COPD/Chronic Bronchitis. NAC PO may ↓exacerbation in certain COPD pts, per ACCP,7 GOLD;8 but doesn’t improve QOL or lung fxn, per meta-analysis9
By vgreene, 21 April, 2020 Flu sx. NAC 600 mg PO bid x6mo assoc w/ ↓clinical flu sx though influenza A/H1N1 infxn rate unchanged, in RCT (N=262 pts, most 65+ yo)6
By vgreene, 21 April, 2020 Pulmonary fibrosis trial. Phase 2 RCT in China examining multi-herb Chinese medicine remedy Fuzheng Huayu on COVID-19 pulm fibrosis in adults; NAC capsules PO tid used in standard tx/control arm5
By vgreene, 21 April, 2020 Immunity hypothesis. Proposed as immune booster & detoxifier (antioxidant, free-radical fighter); anti-inflammatory (eg, for excessive immune response assoc w/ severe COVID dz); resp tract remedy3
By vgreene, 21 April, 2020 Antiviral hypothesis. Purported to ↓ epithelial cell SARS-CoV-2 entry based on in vitro data. Nebulized heparin + NAC (“H-NAC”) proposed as COVID tx2